Guideline evidence review finds almost no data on weight drugs in PCOS

A systematic review published February 14, 2024, in Obesity Reviews found that published research on anti-obesity medications for polycystic ovary syndrome (PCOS) is "very limited," despite growing interest in drugs like semaglutide for women with the condition ^[1]. The review was commissioned to help write the anti-obesity medication section of the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS, a guideline endorsed by 40 medical societies worldwide ^[2].

Researchers searched four medical databases — Medline, EMBASE, PsycInfo, and CINAHL — through July 2022, limiting their search to the past 10 years to focus on newer drugs ^[1]. They found only 11 trials that qualified, covering 545 participants who received an anti-obesity drug and 451 who received a comparison treatment, across 12 different drug comparisons ^[1].

That pool was too small and too varied to combine into a full analysis for most drugs. Formal meta-analysis was only possible for two comparisons: exenatide versus metformin, and orlistat plus a combined oral contraceptive pill versus the pill alone ^[1]. Neither showed a benefit on androgen hormone levels or broader metabolic health. The one significant difference found was that metformin lowered fasting blood glucose slightly more than exenatide did, by 0.10 mmol/L ^[1]. For orlistat plus the contraceptive pill, there was no meaningful difference in fasting insulin compared with the pill alone, and the results varied a lot between the two trials that were combined ^[1].

Outside of the formal meta-analyses, the review's authors noted that in descriptive comparisons, liraglutide, semaglutide, and orlistat appeared to outperform placebo on measures like weight and body size ^[1]. But because so few trials existed, these comparisons could not be statistically combined or confirmed with the same confidence as the meta-analyzed results ^[1].

The review also explains a notable gap: no data on tirzepatide, the drug sold as Mounjaro and Zepbound, existed at the time the search closed in mid-2022 ^[1]. That is why the 2023 PCOS guideline does not mention tirzepatide at all — the drug simply had no published PCOS trial evidence to review ^[1].

Why it matters for patients

PCOS affects a large number of women of reproductive age and is linked to higher rates of obesity, insulin resistance, and metabolic complications ^[1]. Many patients and doctors have looked to GLP-1 drugs as an option given their success in general obesity and diabetes care. But this review shows that formal, PCOS-specific evidence for these drugs remains thin. Only two drug comparisons had enough trials to statistically analyze, and neither found the clear metabolic or hormonal benefits some might expect ^[1].

This does not mean the drugs do not work for women with PCOS. It means the specific, rigorous evidence proving how well they work — and for which PCOS symptoms — has not yet been built. The guideline authors explicitly flagged anti-obesity medications in PCOS as a "high priority" area for future research ^[1]. Patients considering these drugs for PCOS-related symptoms are working with less certainty than patients using them for general weight loss or type 2 diabetes, where trial evidence is far more extensive.

What happens next

The review's authors call for more and larger trials specifically testing anti-obesity drugs in women with PCOS ^[1]. Because the literature search closed in July 2022, newer drugs and larger trials published since then, including any tirzepatide data, were not part of this review and are not reflected in the 2023 guideline ^[1][2]. No date has been set for when the guideline or its evidence base will next be updated to include newer trial data.